Forging a better environment, diversified investment structure

Hangzhou has constantly strived to improve the working efficiency of government services and develop a world-class business environment for global investors.

Pfizer Inc, the world's largest pharmaceutical firm, broke ground for a state-of-the-art global biotechnology center in the Hangzhou Economic Development Area in 2016. Within less than two years, the project went into operation.

We hope to bring the latest technology to Hangzhou and the best quality and most effective drugs to China, with the hope of contributing to the economic development of Hangzhou, said Wang Yingqun, general manager of Pfizer Biopharmaceutical (Hangzhou).

Aside from foreign capital, Hangzhou has also attracted an increasing number of domestic investments over the years. Last year, a total of 1,048 projects from overseas Zhejiang merchants were introduced, with a paid-in investment value totaling 86.92 billion yuan, a year-on-year increase of 14.09 percent.

The information economy, advanced manufacturing, and biopharmaceutical industries are among the key focuses of investments in Hangzhou.